FDA will publicly signal (via guidance mention, workshop, or advisory framing) that any ibogaine IND requires mandatory continuous QT/telemetry monitoring protocols before dosing expansion.

The FDA (the US drug regulator) looks set to publicly state that any research program testing ibogaine must include continuous heart monitoring before it can give more people the drug. Ibogaine can cause a dangerous heart rhythm problem, and the FDA wants proof that researchers are watching for it. This matters because it sets a safety floor that every ibogaine study must clear before it can grow.

Torsadogenic risk is non-negotiable for me; I've seen the political heat and will insist safeguards precede access to protect both patients and the agency.